Dr. Maroua Khalifa serves as the Associate Director of Pharmaceutical Development at Thryv Therapeutics, where she leads CMC operations across multiple programs. Prior to joining Thryv, Dr. Khalifa was a consultant at Gladius Pharmaceuticals, where she successfully scaled up the synthesis of the lead candidate to gram scale for preclinical studies targeting multi-drug-resistant bacterial infections.

Earlier in her career, Dr. Khalifa worked as a project manager at Novalix-Tunisia, where she played a pivotal role in establishing the first R&D laboratory in North Africa, laying the foundation for future research and development initiatives in the region.

Dr. Khalifa holds a bachelor’s and master's degree in Organic Chemistry from the Université de Monastir in Tunisia. She earned her Ph.D. in Organic Chemistry from the Université de Montréal, where she developed an innovative intramolecular C-H amination reaction using a Rhodium complex catalyst. This methodology contributed to the formal synthesis of (-)-Cytoxazone, a selective immunomodulator that inhibits the signaling pathway of Th2 cells.